Literature DB >> 21761921

Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.

Samia Ait-Mohand1, Patrick Fournier, Véronique Dumulon-Perreault, Garry E Kiefer, Paul Jurek, Cara L Ferreira, François Bénard, Brigitte Guérin.   

Abstract

Several bifunctional chelates (BFCs) were investigated as carriers of (64)Cu for PET imaging. The most widely used chelator for (64)Cu labeling of BFCs is DOTA (1,4,7,10-tetraazacyclododecane-N,N',N″,N'''-tretraacetic acid), even though this complex exhibits only moderate in vivo stability. In this study, we prepared a series of alternative chelator-peptide conjugates labeled with (64)Cu, measured in vitro receptor binding affinities in human breast cancer T47D cells expressing the gastrin-releasing peptide receptor (GRPR) and compared their in vivo stability in mice. DOTA-, NOTA-(1,4,7-triazacyclononane-1,4,7-triacetic acid), PCTA-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid), and Oxo-DO3A-(1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid) peptide conjugates were prepared using H(2)N-Aoc-[d-Tyr(6),βAla(11),Thi(13),Nle(14)]bombesin(6-14) (BBN) as a peptide template. The BBN moiety was selected since it binds with high affinity to the GRPR, which is overexpressed on human breast cancer cells. A convenient synthetic approach for the attachment of aniline-BFC to peptides on solid support is also presented. To facilitate the attachment of the aniline-PCTA and aniline-Oxo-DO3A to the peptide via an amide bond, a succinyl spacer was introduced at the N-terminus of BBN. The partially protected aniline-BFC (p-H(2)N-Bn-PCTA(Ot-Bu)(3) or p-H(2)N-Bn-DO3A(Ot-Bu)(3)) was then coupled to the resulting N-terminal carboxylic acid preactivated with DEPBT/ClHOBt on resin. After cleavage and purification, the peptide-conjugates were labeled with (64)Cu using [(64)Cu]Cu(OAc)(2) in 0.1 M ammonium acetate buffer at 100 °C for 15 min. Labeling efficacy was >90% for all peptides; Oxo-DO3A-BBN was incubated an additional 150 min at 100 °C to achieve this high yield. Specific activities varied from 76 to 101 TBq/mmol. Competition assays on T47D cells showed that all BFC-BBN complexes retained high affinity for the GRPR. All BFC-BBN (64)Cu-conjugates were stable for over 20 h when incubated at 37 °C in mouse plasma samples. However, in vivo, only 37% of the (64)Cu/Oxo-DO3A complex remained intact after 20 h while the (64)Cu/DOTA-BBN complex was completely demetalated. In contrast, both (64)Cu/NOTA- and (64)Cu/PCTA-BBN conjugates remained stable during the 20 h time period. Our results indicate that it is possible to successfully conjugate aniline-BFC with peptide on solid support. Our data also show that (64)Cu-labeled NOTA- and PCTA-BBN peptide conjugates are promising radiotracers for PET imaging of many human cancers overexpressing the GRP receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21761921     DOI: 10.1021/bc2002665

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  22 in total

1.  Design of a multivalent bifunctional chelator for diagnostic 64Cu PET imaging in Alzheimer's disease.

Authors:  Hong-Jun Cho; Truc T Huynh; Buck E Rogers; Liviu M Mirica
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-24       Impact factor: 11.205

Review 2.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

3.  Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.

Authors:  Yuping Xu; Donghui Pan; Chen Zhu; Qing Xu; Lizhen Wang; Fei Chen; Runlin Yang; Shineng Luo; Min Yang; Yongjun Yan
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

4.  Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer.

Authors:  Nerissa Therese Viola-Villegas; Sean D Carlin; Ellen Ackerstaff; Kuntal K Sevak; Vadim Divilov; Inna Serganova; Natalia Kruchevsky; Michael Anderson; Ronald G Blasberg; Oleg A Andreev; Donald M Engelman; Jason A Koutcher; Yana K Reshetnyak; Jason S Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-01       Impact factor: 11.205

5.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

6.  Pycup--a bifunctional, cage-like ligand for (64)Cu radiolabeling.

Authors:  Eszter Boros; Elena Rybak-Akimova; Jason P Holland; Tyson Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Reza Latifi; Peter Caravan
Journal:  Mol Pharm       Date:  2013-12-11       Impact factor: 4.939

7.  A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.

Authors:  Yang Liu; Xiang Hu; Hongguang Liu; Lihong Bu; Xiaowei Ma; Kai Cheng; Jinbo Li; Mei Tian; Hong Zhang; Zhen Cheng
Journal:  J Nucl Med       Date:  2013-11-06       Impact factor: 10.057

8.  (18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor.

Authors:  Ying Li; Zhibo Liu; Curtis W Harwig; Maral Pourghiasian; Joseph Lau; Kuo-Shyan Lin; Paul Schaffer; Francois Benard; David M Perrin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

9.  Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivo complex stability.

Authors:  Ningjie Wu; Chi Soo Kang; Inseok Sin; Siyuan Ren; Dijie Liu; Varyanna C Ruthengael; Michael R Lewis; Hyun-Soon Chong
Journal:  J Biol Inorg Chem       Date:  2015-12-14       Impact factor: 3.358

10.  Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging.

Authors:  Patrick Fournier; Véronique Dumulon-Perreault; Samia Ait-Mohand; Réjean Langlois; François Bénard; Roger Lecomte; Brigitte Guérin
Journal:  EJNMMI Res       Date:  2012-02-14       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.